Economical aspect of biological therapy in inflammatory conditions in Hungary

Abstract

Introduction: There has been a burst in the use of biological therapies in the past decade resulting in increasing costs. In 2006 – 2010 the following biological agents were available in Hungary: adalimumab, certolizumab, etanercept, golimumab, infliximab, rituximab, tocilizumab, and ustekinumab. All biological agents except rituximab were first line therapies; rituximab was a second line option in rheumatoid arthritis.

Areas covered: Data of the financing system related to health care services from the data warehouse of the Hungarian National Health Insurance Fund were in inflammatory conditions. Our analysis showed a constant increase in number of patients and overall cost of biological therapy as well as annual cost of biological agents. Distribution of first choice of biological therapy was compared in different diseases. Time from diagnosis to start of biological therapy showed relatively high deviations.

Expert opinion: In order to achieve both health benefit and cost-effectiveness it is crucial that biological therapy is initiated early enough in the course of the disease, after the failure of non-biological therapies. Health authorities in close collaboration with clinical decision-makers should ensure that early detection of the disease and early initiation of appropriate therapies—including non-biological and biological therapies—are carried out in the health care systems.

Keywords::

• biological therapy
• cost
• cost effective
• inflammation
• personalized therapy

Acknowledgment

The authors are thankful to the auditors of the local offices of the NHIF for performing the national audit and providing useful data for analysis and to P. P. Tak for permitting us to use Figure 2.

Notes

This box summarizes key points contained in the article.